MetaCap

Protagonist Therapeutics Inc. (PTGX)

NASDAQ: PTGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

121.40-2.62 (-2.11%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PTGX stock chart

Technical analysis

Key statistics

All statistics
52-week range
77.00 – 160.81
Day range
120.15 – 125.74
Volume / Avg
600.73K / 668.45K
Beta
—

52-week range

$77.00$160.81

PTGX stock today

On Nov 20, PTGX ended the session at $121.40, shedding $2.62 (2.11%), versus the S&P 500's 3.70% decline. Shares are 24.5% below their 52-week high of $160.81, set on Aug 19, 2026 and 57.7% above the 52-week low of $77.00, in the middle of the past year's range. PTGX is up 39.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 42.2%.

Protagonist Therapeutics trades at 25.7x its trailing twelve-month earnings per share of $4.73. Its forward P/E of 348.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Protagonist Therapeutics

Company profile

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Dinesh V. Patel Ph.D.
Headquarters
Newark, CA
Employees
149
IPO year
2016

Financial highlights

Full financials

In fiscal 2025, Protagonist Therapeutics generated $46.0 million in revenue, down 89.4% from fiscal 2024, its first annual decline since 2022. Protagonist Therapeutics reported a net loss of $130.1 million, compared with net income of $275.2 million a year earlier. Operating margin was -343.6%.

Protagonist Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$46.02M$434.43M$60.00M$26.58M$27.36M
Growth-89.41%+624.05%+125.73%-2.84%-4.44%
Net income$-130.15M$275.19M$-78.95M$-127.39M$-125.55M
EPS (diluted)$-2.05$4.23$-1.39$-2.60$-2.71

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$182.36+50.21%

  • Strong buy 3
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $151.00High $225.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.62 vs $2.58
Surprise
-124.03%

PTGX news

All PTGX news

Protagonist Therapeutics peers

Health Care sector
PTGX peer companies
CompanyPrice% ChgMarket capCompare
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs PTGX
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs PTGX
ALKSAlkermes plc44.94-2.69%$7.55Bvs PTGX
PRAXPraxis Precision Medicines Inc.300.43-3.37%$8.40Bvs PTGX
KNSAKiniksa Pharmaceuticals International plc Class A93.90+0.38%$7.38Bvs PTGX
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs PTGX
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs PTGX
MDGLMadrigal Pharmaceuticals Inc.379.10-4.45%$8.81Bvs PTGX

Indexes, lists and sector

Protagonist Therapeutics stock FAQ

What is Protagonist Therapeutics's stock price today?

PTGX last traded at $121.40 as of Nov 20, 4:00 PM EST, down 2.11% on the day. Prices are delayed at least 15 minutes.

What is PTGX's P/E ratio?

PTGX trades at a trailing P/E ratio of 25.67 and a forward P/E of 348.79.

Who is Protagonist Therapeutics's CEO?

Dr. Dinesh V. Patel Ph.D. is the chief executive officer of Protagonist Therapeutics Inc., which has about 149 employees.

What is the PTGX 52-week high?

The 52-week high for PTGX is $160.81 and the 52-week low is $77.00. The stock is currently 24.5% below its high.

Compare PTGX